<DOC>
	<DOCNO>NCT01107912</DOCNO>
	<brief_summary>The 5-milligram ( mg ) maintenance dose ( MD ) prasugrel elderly patient coronary artery disease produce pharmacodynamic response within therapeutic range 10-mg MD non-elderly patient .</brief_summary>
	<brief_title>Comparison Prasugrel Clopidogrel Very Elderly Non-Elderly Patients With Stable Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Participants ( Either : least 45 year age , less 65 year age OR 75 year age old ) history stable coronary artery disease currently indicate treatment thienopyridine ( , prasugrel , clopidogrel , ticlopidine ) Provision write informed consent Body weight great equal 60 kilogram ( kg ) For woman childbearing potential ( , woman surgically chemically sterilise menarche 1 year post menopause ) , test negative pregnancy ( base urine serum pregnancy test perform randomisation ) agree use reliable method birth control study Unstable coronary artery disease Myocardial Infarction ( MI ) within previous 30 day Percutaneous Coronary Intervention ( PCI ) Coronary Artery Bypass Graft Surgery ( CABG ) within previous 90 day History refractory ventricular arrhythmia within last 6 month ; implant defibrillator device ; congestive heart failure within 6 month prior screen ; major surgery , severe trauma , fracture organ biopsy within 3 month prior enrollment Any plan surgical procedure coronary revascularisation ( surgical percutaneous ) plan within 60 day follow randomisation Any known contraindication treatment antiplatelet agent Significant hypertension time screen randomisation Clinically significant outofrange value platelet count haemoglobin screening , investigator 's opinion , result clinical laboratory test time screen judge clinically significant study population , determine investigator Prior history presence significant bleeding disorder , abnormal bleeding tendency , personal history coagulation bleeding disorder Prior history clinical suspicion cerebral vascular malformation , intracranial neoplasm , Transient Ischemic Attack ( TIA ) stroke Prior history thrombocytopenia thrombocytosis Use antiplatelet agent ( besides aspirin ) within 10 day prior screen ; use ( plan use ) heparin , oral anticoagulant , fibrinolytic agent within 30 day screen ; participant receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDS ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Platelet function</keyword>
</DOC>